睿知中国医院研究地图
候选清单

武汉武汉大学

武汉大学人民医院

Renmin Hospital of Wuhan University

在本站收录的 53 种疾病中,这家医院列在其中 19 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

武汉大学人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma13 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文牵头 2 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma87 篇牵头论文
  4. 胃癌Stomach cancer74 篇牵头论文牵头 1 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma5 篇牵头论文
  6. 骨肉瘤Osteosarcoma31 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma10 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  10. 重症肌无力Myasthenia gravis0 篇牵头论文
  11. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
  12. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  13. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis3 篇牵头论文
  14. 白塞病Behçet disease2 篇牵头论文
  15. Alport 综合征Alport syndrome0 篇牵头论文
  16. IgA 肾病IgA nephropathy2 篇牵头论文
  17. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  18. 家族性腺瘤性息肉病Familial adenomatous polyposis2 篇牵头论文
  19. Leber 遗传性视神经病变Leber hereditary optic neuropathy2 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.5%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 5520232024: 1120242025: 112025

武汉有 6 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  2. 正在招募
    Immune Score Based Radiomics in Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2021-11
    登记号
    NCT05126160

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:浙江省肿瘤医院;另有 4 家列出的医院为研究中心宁波、杭州、武汉、温州

  3. 正在招募
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    分期
    I期
    开始
    2021-11
    登记号
    NCT05194982

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心广州、武汉、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题影像与人工智能复发与转移放疗技术
论文中的科室耳鼻喉/头颈外科

这些论文过半是实验室或动物研究。

牵头的论文13
  1. Homing Effect Directed Cuprous Delivery Activates Cuproptosis Against Nasopharyngeal Carcinoma and Metastasis.2026Small (Weinheim an der Bergstrasse, Germany)
  2. Molecular network analysis of CPEB4 translational control and targeting CPEB4/β-catenin to modulate invasion and migration of nasopharyngeal carcinoma cells.2025International journal of medical sciences免费全文
  3. CENPN suppresses autophagy and increases paclitaxel resistance in nasopharyngeal carcinoma cells by inhibiting the CREB-VAMP8 signaling axis.2024Autophagy免费全文
  4. Predicting prognosis of nasopharyngeal carcinoma based on deep learning: peritumoral region should be valued.2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  5. Deep Learning for Predicting Distant Metastasis in Patients with Nasopharyngeal Carcinoma Based on Pre-Radiotherapy Magnetic Resonance Imaging.2023Combinatorial chemistry & high throughput screening免费全文
  6. MiR-3612 targeting THBS1 suppresses nasopharyngeal carcinoma progression by PI3K/AKT signaling pathway.2023Human & experimental toxicology
  7. Enhancing nasopharyngeal carcinoma cell radiosensitivity by suppressing AKT/mTOR via CENP-N knockdown.2023Journal of translational medicine免费全文
  8. Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor.2023The Journal of pharmacy and pharmacology
  9. (S,R)3-(4-Hydroxyphenyl)-4,5-Dihydro-5-Isoxazole Acetic Acid Methyl Ester Inhibits Epithelial-to-Mesenchymal Transition Through TGF-β/Smad4 Axis in Nasopharyngeal Carcinoma.2022Anti-cancer agents in medicinal chemistry
  10. Deep learning for locally advanced nasopharyngeal carcinoma prognostication based on pre- and post-treatment MRI.2022Computer methods and programs in biomedicine
  11. LncRNA FAM225A activates the cGAS-STING signaling pathway by combining FUS to promote CENP-N expression and regulates the progression of nasopharyngeal carcinoma.2022Pathology, research and practice
  12. Overexpression of Notch2 enhances radiosensitivity via inhibition of the AKT/mTOR signaling pathway in nasopharyngeal carcinoma.2021Bioengineered免费全文
  13. Ginkgolic Acid Suppresses Nasopharyngeal Carcinoma Growth by Inducing Apoptosis and Inhibiting AKT/NF-κB Signaling.2021Journal of medicinal food
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  2. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor正在招募NCT05194982研究中心I期2021-11 启动
  3. Immune Score Based Radiomics in Nasopharyngeal Carcinoma正在招募NCT05126160研究中心2021-11 启动
  4. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)进行中,不再招募NCT05587374研究中心III期2023-08 启动
PubMed 以外找到的论文(未计入)16
  1. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncology论文
  2. Evaluation of Trident network against atlas and 2D U-net methods for auto-segmentation of organs at risk in nasopharyngeal carcinoma: a comparative study2025Frontiers in Physics论文
  3. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  4. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  5. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  6. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  7. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  8. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  9. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  10. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  11. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  12. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  13. Boosting Advanced Nasopharyngeal Carcinoma Stage Prediction Using a Two-Stage Classification Framework Based on Deep Learning2021International Journal of Computational Intelligence Systems论文
  14. Correction to: Boosting Advanced Nasopharyngeal Carcinoma Stage Prediction Using a Two‑Stage Classification Framework Based on Deep Learning2021International Journal of Computational Intelligence Systems勘误
  15. Long Non-coding RNA PANDAR Promotes Radioresistance in Nasopharyngeal Carcinoma via SIRT1/Ku70/PI3K/Akt Pathway2021Research Square预印本
  16. S100A14 Induces Apoptosis and Negatively Regulates Proliferation of Nasopharyngeal Carcinoma Cells2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。

牵头论文
12
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 4420232024: 1120242025: 442025

武汉有 5 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
    分期
    未注明
    开始
    2023-05
    登记号
    NCT05894369

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:武汉大学人民医院武汉

  2. 正在招募
    A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
    分期
    III期
    开始
    2023-07
    登记号
    NCT05919030

    年龄 18 岁 至 未注明(登记的条件)

    牵头:武汉大学人民医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗免疫治疗新辅助与综合治疗
论文中的科室消化/肝病科肿瘤内科
牵头的论文12
  1. Elaiophylin targets EIF4B to suppress the growth of esophageal squamous cell carcinoma via the PI3K/AKT signaling pathway.2025Cancer letters
  2. Porphyromonas gingivalis extracellular vesicles promotes tumor metastasis in esophageal squamous cell carcinoma by inducing PRKACB/JNK/ NFATC2 axis.2025Journal of nanobiotechnology免费全文
  3. Immune Cellular Patterns Predicting Lymph Node Status Helps Personalized Management of Stage T1 Esophageal Squamous Cell Carcinoma.2025Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  4. Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.2025Thoracic cancer免费全文
  5. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  6. Human-Like Artificial Intelligent System for Predicting Invasion Depth of Esophageal Squamous Cell Carcinoma Using Magnifying Narrow-Band Imaging Endoscopy: A Retrospective Multicenter Study.2023Clinical and translational gastroenterology免费全文
  7. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway.2023Gut microbes免费全文
  8. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  9. Fusobacterium nucleatum promotes proliferation in oesophageal squamous cell carcinoma via AHR/CYP1A1 signalling.2023The FEBS journal
  10. KISS-1, Mediated by Promoter Methylation, Suppresses Esophageal Squamous Cell Carcinoma Metastasis via MMP2/9/MAPK Axis.2022Digestive diseases and sciences
  11. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.2022JAMA network open免费全文
  12. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma正在招募NCT05919030牵头方III期2023-07 启动
  2. Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma正在招募NCT05894369牵头方2023-05 启动
  3. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
PubMed 以外找到的论文(未计入)13
  1. The Transcription Factor ELK1 Promotes Esophageal Squamous Cell Carcinoma Progression by Activating the CDK4/Wnt/β-catenin Pathway2025Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents论文
  2. Novel Roles of HOXD11 and HOXD13 in Mediating Response to Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  3. Prediction of lymph node status in stage T1 esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  4. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  5. A prospective clinical trial of camrelizumab in combination with chemoradiotherapy in patients with metastatic esophageal squamous cell carcinoma.2022Journal of Clinical Oncology会议摘要
  6. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  7. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  8. Prognosis and Benefit Factors of Definitive Concurrent Chemoradiotherapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma2022International Journal of Radiation Oncology*Biology*Physics论文
  9. Relationship between ENO1 and Metastasis Risk and Prognosis in Esophageal squamous cell carcinoma2022Research Square预印本
  10. Clinical Parameters Predicting Prognosis for Elderly Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma2021International Journal of Radiation Oncology*Biology*Physics论文
  11. Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cancer Cells via the PI3K/AKT Signaling Pathway2021Research Square预印本
  12. Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cell Carcinoma via the PI3K/AKT Signaling Pathway2021Research Square预印本
  13. Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cell Carcinoma via the PI3K/AKT Signaling Pathway2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 87 篇,占 0.6%。

牵头论文
87
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 171720222023: 262620232024: 191920242025: 14142025

武汉有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室普外/肝胆胰外科消化/肝病科病理/检验科肿瘤内科
牵头的论文87
  1. Matrix stiffening-driven hepatocellular carcinoma progression through OASL-mediated cGAS-STING repression and subsequent macrophage activation.2026International immunopharmacology
  2. Structurally diverse tetrahydroxanthone analogues from Paraconiothyrium sp. AC31 with pyroptosis induction through targeted inhibition of PARP1 in hepatocellular carcinoma cells.2025Bioorganic chemistry
  3. CYP8B1 inhibits hepatocellular carcinoma progression by repressing PAK4 transcription through inhibition of nuclear translocation of u-STAT1.2025Cell death & disease免费全文
  4. Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors.2025Frontiers in immunology免费全文
  5. Comprehensive analysis of mitochondrial solute carrier family 25 (SLC25) identifies member 19 (SLC25A19) as a regulatory factor in hepatocellular carcinoma.2025Gene
  6. The prognostic significance and potential mechanism of PFDN4 in hepatocellular carcinoma.2025International immunopharmacology
  7. NSMCE2 promotes the occurrence and development of HCC by regulating the SUMOylation of PPARα.2025International immunopharmacology
  8. Multi-Omics Integration: Predicting Progression and Optimizing Clinical Treatment of Hepatocellular Carcinoma Through Malignant-Cell-Related Genes.2025International journal of molecular sciences免费全文
  9. Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients.2025Journal of experimental & clinical cancer research : CR免费全文
  10. Metal-organic framework nanoparticles activate cGAS-STING pathway to improve radiotherapy sensitivity.2025Journal of nanobiotechnology免费全文
  11. m6A-modified circCCAR1 promotes malignant proliferation by enhancing KIF5B expression in hepatocellular carcinoma.2025Journal of physiology and biochemistry
  12. m6A regulators-based gene expression pattern is associated with immune microenvironment characteristics in hepatocellular carcinoma.2025Scientific reports免费全文
  13. Single-cell landscape of dynamic changes in CD8+ T cells, CD4+ T cells and exhausted T cells in hepatocellular carcinoma.2025Scientific reports免费全文
  14. Nanodelivery of Y-27632 by RGD-modified liposome enhances radioimmunotherapy of hepatocellular carcinoma via tumor microenvironment matrix stiffness reprogramming.2025Theranostics免费全文
  15. The Role of HBx Mutations in Chronic Hepatitis B with Acute Exacerbation.2025Viruses免费全文
  16. Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy.2024Annals of medicine免费全文
  17. C-X-C motif chemokine receptor 4 inhibition promotes the effect of plantamajoside in hepatocellular carcinoma.2024Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  18. Matrix stiffness-related extracellular matrix signatures and the DYNLL1 protein promote hepatocellular carcinoma progression through the Wnt/β-catenin pathway.2024BMC cancer免费全文
  19. Knockdown of SLC16A3 decreases extracellular lactate concentration in hepatocellular carcinoma, alleviates hypoxia and induces ferroptosis.2024Biochemical and biophysical research communications
  20. USP30 promotes the progression of breast cancer by stabilising Snail.2024Cancer gene therapy免费全文
  21. Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.2024Cancer medicine
  22. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.2024Frontiers in bioscience (Landmark edition)
  23. IGFALS suppresses hepatocellular carcinoma progression by stabilizing PPAR-γ.2024International immunopharmacology
  24. Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases.2024International immunopharmacology
  25. S100A16 is a potential target for reshaping the tumor microenvironment in the hypoxic context of liver cancer.2024International immunopharmacology
  26. Association between ascites Gustave Roussy immune score and the intratumoural microbiome in malignant ascites secondary to hepatocellular carcinoma.2024International immunopharmacology
  27. A review of deep learning approaches for multimodal image segmentation of liver cancer.2024Journal of applied clinical medical physics免费全文
  28. Deciphering the molecular interplay and tumorigenesis in hepatocellular carcinoma through insights into FBXL6 and KRASG12D.2024Military Medical Research免费全文
  29. Transcription factor RELA promotes hepatocellular carcinoma progression by promoting the transcription of m6A modulator METTL3.2024Pathology, research and practice
  30. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.2024PeerJ免费全文
  31. High tumor burden score indicated the unfavorable prognosis in patients with hepatocellular carcinoma: A meta-analysis.2024PloS one免费全文
  32. Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma.2024Scientific reports免费全文
  33. The prognostic significance and potential mechanism of DBF4 zinc finger in hepatocellular carcinoma.2024Scientific reports免费全文
  34. Ascitic microbiota alteration is associated with portal vein tumor thrombosis occurrence and prognosis in hepatocellular carcinoma.2024mBio免费全文
  35. Apoprotein E methylation is correlated with immune microenvironment in hepatocellular carcinoma.2023Acta oncologica (Stockholm, Sweden)
  36. Prognostic value and immunological role of CSNK1D in human cancers.2023Aging免费全文
  37. A comprehensive survival and prognosis analysis of GPR55 expression in hepatocellular carcinoma.2023Aging免费全文
  38. Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma.2023Aging免费全文
  39. ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma.2023BMC medical genomics免费全文
  40. Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma.2023BMC medical genomics免费全文
  41. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic mo2023Cancer immunology, immunotherapy : CII免费全文
  42. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma.2023Cancer medicine免费全文
  43. GNB1 promotes hepatocellular carcinoma progression by targeting BAG2 to activate P38/MAPK signaling.2023Cancer science免费全文
  44. USP25 promotes hepatocellular carcinoma progression by interacting with TRIM21 via the Wnt/β-catenin signaling pathway.2023Chinese medical journal免费全文
  45. FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis.2023Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  46. Targeting WDxR motif reprograms immune microenvironment and inhibits hepatocellular carcinoma progression.2023EMBO molecular medicine免费全文
  47. Nomogram model for predicting esophsagogastric varices in hepatocellular carcinoma with cirrhosis.2023European journal of gastroenterology & hepatology
  48. Construction and validation of a nomogram for patients with multiple hepatocellular carcinoma: A SEER-based study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  49. KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway.2023Experimental cell research
  50. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.2023International immunopharmacology
  51. High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers.2023Journal of cachexia, sarcopenia and muscle免费全文
  52. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on NK cell marker genes to predict prognosis and immunotherapy response in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  53. The application of nanoparticles in immunotherapy for hepatocellular carcinoma.2023Journal of controlled release : official journal of the Controlled Release Society
  54. Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.2023Journal of hepatology
  55. Recent updates on targeting the molecular mediators of NAFLD.2023Journal of molecular medicine (Berlin, Germany)
  56. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma.2023Journal of translational medicine免费全文
  57. Evaluation of Serum FGL1 as Diagnostic Markers for HBV-Related Hepatocellular Carcinoma.2023Laboratory medicine
  58. Two fragments of HBV DNA integrated into chrX: 11009033 and its genetic regulation in HepG2.2.15.2023Molecular medicine reports免费全文
  59. Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients.2023PloS one免费全文
  60. Characteristics of lactate metabolism phenotype in hepatocellular carcinoma.2023Scientific reports免费全文
  61. Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma.2022Biomolecules免费全文
  62. PSMD12 promotes the activation of the MEK-ERK pathway by upregulating KIF15 to promote the malignant progression of liver cancer.2022Cancer biology & therapy免费全文
  63. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  64. USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling.2022Cell death & disease免费全文
  65. Differential expression of insulin-like growth factor type 1 receptor identifies heterogeneous intrahepatic regulatory T subsets in mouse hepatocellular carcinoma.2022Clinical and experimental immunology
  66. RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma.2022Clinical and experimental medicine
  67. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.2022Current oncology (Toronto, Ont.)免费全文
  68. Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study.2022Expert review of gastroenterology & hepatology
  69. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.2022Frontiers in immunology免费全文
  70. Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  71. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.2022Genes免费全文
  72. Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.2022Hepatology (Baltimore, Md.)
  73. Declining disease burden of HCC in the United States, 1992-2017: A population-based analysis.2022Hepatology (Baltimore, Md.)
  74. CircRNA_0040705 promotes the progression of hepatocellular carcinoma.2022IUBMB life
  75. Protein succinylation associated with the progress of hepatocellular carcinoma.2022Journal of cellular and molecular medicine免费全文
  76. Research Progress in Alpha-fetoprotein-induced Immunosuppression of Liver Cancer.2022Mini reviews in medicinal chemistry
  77. ROS-Related miRNAs Regulate Immune Response and Chemoradiotherapy Sensitivity in Hepatocellular Carcinoma by Comprehensive Analysis and Experiment.2022Oxidative medicine and cellular longevity免费全文
  78. ADAM15 correlates with prognosis, immune infiltration and apoptosis in hepatocellular carcinoma.2021Aging免费全文
  79. Identification of a Nine Immune-Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma.2021BioMed research international免费全文
  80. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients2021Clinics and research in hepatology and gastroenterology
  81. Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.2021Human & experimental toxicology
  82. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.2021International immunopharmacology
  83. Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.2021Laboratory medicine
  84. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.2021Life sciences
  85. Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome.2021Oxidative medicine and cellular longevity免费全文
  86. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma.2021Oxidative medicine and cellular longevity免费全文
  87. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.2021Pathology, research and practice
中文论文(未计入)2
  1. [Hepatoid adenocarcinoma of the stomach metastatic to liver: a clinicopathological analysis of 3 cases].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Primary hepatoid adenocarcinoma in lung, gallbladder and bladder: a clinicopathological observation of three cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  2. Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma已终止NCT03349255研究中心I期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 74 篇,占 0.8%。

牵头论文
74
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 212120212022: 9920222023: 141420232024: 131320242025: 15152025

武汉有 5 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
    分期
    未注明
    开始
    2020-12
    登记号
    NCT03972956

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:武汉大学人民医院武汉

  2. 正在招募
    Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
    分期
    未注明
    开始
    2026-02
    登记号
    NCT07401199

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心武汉、石家庄

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜影像与人工智能免疫与靶向药物
论文中的科室消化/肝病科普外/肝胆胰外科肿瘤内科病理/检验科
牵头的论文74
  1. Artificial intelligence assistance narrows the experience gap in endoscopic reporting of gastric lesions: a prospective clinical trial.2026Surgical endoscopy免费全文
  2. Efficacy of endoscopic therapy in patients with T1b gastric cancer and construction of a prognostic prediction model: a retrospective cohort study and multicenter validation study.2026Surgical endoscopy免费全文
  3. Amylin inhibits gastric cancer progression by targeting CCN1 and affecting the PI3K/AKT signalling pathway.2025Annals of medicine免费全文
  4. Global status and attributable risk factors of esophageal, stomach, colorectal cancers in adolescents and young adults: global burden of disease 2021 study analysis.2025BMC cancer免费全文
  5. Clinical implications of DNA ploidy, stroma, and nucleotyping in predicting peritoneal metastasis risk for gastric cancer.2025BMC cancer免费全文
  6. Development and verification of a radiomics model to forecast Ki67 index and prognosis in advanced gastric tubular adenocarcinoma.2025BMC gastroenterology免费全文
  7. Screening and surveillance of hereditary upper GI cancers.2025Best practice & research. Clinical gastroenterology
  8. LncRNA FIRRE drives gastric cancer progression via ZFP64-mediated TUBB3 promoter activation.2025Cancer letters
  9. Comprehensive proteomic analysis and multidimensional model construction of peritoneal metastasis in gastric cancer.2025Cancer letters
  10. SIRT1 Expression in Human Gastrointestinal Tumors and Its Clinical Significance.2025Cancer medicine免费全文
  11. Clinical decision tree for optimizing endoscopic assessment of signet ring cell carcinoma in hereditary diffuse gastric cancer surveillance.2025Endoscopy
  12. The mechanism of Weiqi decoction treating gastric cancer: a work based on network pharmacology and experimental verification.2025Hereditas免费全文
  13. Trends in Stomach Cancer Burden in China: A Joinpoint and APC Analysis Based on GBD 2021.2025Journal of gastroenterology and hepatology免费全文
  14. Integrated Genomic Analysis Identifies Clinically Relevant Molecular Subtypes and Disulfidptosis-Related Prognostic Signature of Gastric Cancer.2025Journal of immunotherapy (Hagerstown, Md. : 1997)
  15. A prognostic model for gastric cancer constructed by multiple machine learning algorithms.2025Journal of molecular histology
  16. First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis.2025Molecular cancer therapeutics
  17. Advancements in non-invasive diagnosis of gastric cancer.2025World journal of gastroenterology免费全文
  18. Integrated multi-omics analysis and machine learning identify hub genes and potential mechanisms of resistance to immunotherapy in gastric cancer.2024Aging免费全文
  19. System-wide identification of novel de-ubiquitination targets for USP10 in gastric cancer metastasis through multi-omics screening.2024BMC cancer免费全文
  20. TRIM47 drives gastric cancer cell proliferation and invasion by regulating CYLD protein stability.2024Biology direct免费全文
  21. Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers.2024Clinical nutrition (Edinburgh, Scotland)
  22. An artificial intelligence system for chronic atrophic gastritis diagnosis and risk stratification under white light endoscopy.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  23. Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway.2024Drug design, development and therapy免费全文
  24. Macrophages enhance cisplatin resistance in gastric cancer through the transfer of circTEX2.2024Journal of cellular and molecular medicine免费全文
  25. Gastric neoplasm detection of computer-aided detection-assisted esophagogastroduodenoscopy changes with implement scenarios: a real-world study.2024Journal of gastroenterology and hepatology
  26. The effect of incorporating domain knowledge with deep learning in identifying benign and malignant gastric whitish lesions: A retrospective study.2024Journal of gastroenterology and hepatology
  27. Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  28. Role of ATP citrate lyase and its complementary partner on fatty acid synthesis in gastric cancer.2024Scientific reports免费全文
  29. A risk prediction model for delayed bleeding after ESD for gastric precancerous lesions.2024Surgical endoscopy
  30. Double-nylon purse-string suture in closing postoperative wounds following endoscopic resection of large (≥ 3 cm) gastric submucosal tumors.2024World journal of gastroenterology免费全文
  31. Identification of GNG7 as a novel biomarker and potential therapeutic target for gastric cancer via bioinformatic analysis and in vitro experiments.2023Aging免费全文
  32. Baicalin enhances the efficacy of 5-Fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. Age-specific cardiovascular disease-related mortality among patients with major gastrointestinal cancers: A SEER population-based study.2023Cancer medicine免费全文
  34. Special AT-rich sequence binding protein 1 promotes multidrug resistance in gastric cancer by regulation of Ezrin to alter subcellular localization of ATP-binding cassette transporters.2023Cancer science免费全文
  35. Identifying the key genes of Epstein-Barr virus-regulated tumour immune microenvironment of gastric carcinomas.2023Cell proliferation免费全文
  36. KIFC3 Regulates the progression and metastasis of gastric cancer via Notch1 pathway.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  37. A deep-learning based system using multi-modal data for diagnosing gastric neoplasms in real-time (with video).2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  38. CircSOD2 polarizes macrophages towards the M1 phenotype to alleviate cisplatin resistance in gastric cancer cells by targeting the miR-1296/STAT1 axis.2023Gene
  39. The Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Advanced Esophagogastric Cancer.2023International immunopharmacology
  40. Exploring the challenge of early gastric cancer diagnostic AI system face in multiple centers and its potential solutions.2023Journal of gastroenterology
  41. Thymoquinone induces apoptosis and protective autophagy in gastric cancer cells by inhibiting the PI3K/Akt/mTOR pathway.2023Phytotherapy research : PTR
  42. Targeted labeling with tissue marking dyes guided by magnifying endoscopy of endoscopic submucosal dissection specimen improves the accuracy of endoscopic and histopathological diagnosis of early gastric cancer: a before-after study.2023Surgical endoscopy
  43. The effectiveness of a computer-aided system in improving the detection rate of gastric neoplasm and early gastric cancer: study protocol for a multi-centre, randomized controlled trial.2023Trials免费全文
  44. Comparison of Helicobacter pylori positive and negative gastric cancer via multi-omics analysis.2023mBio免费全文
  45. Key Molecules of Fatty Acid Metabolism in Gastric Cancer.2022Biomolecules免费全文
  46. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  47. miR-137 Modulates Human Gastric Cancer Cell Proliferation, Apoptosis, and Migration by Targeting EZH2.2022Critical reviews in eukaryotic gene expression
  48. Real-time use of artificial intelligence for diagnosing early gastric cancer by magnifying image-enhanced endoscopy: a multicenter diagnostic study (with videos).2022Gastrointestinal endoscopy
  49. Real-time artificial intelligence for detecting focal lesions and diagnosing neoplasms of the stomach by white-light endoscopy (with videos).2022Gastrointestinal endoscopy
  50. Deep learning system compared with expert endoscopists in predicting early gastric cancer and its invasion depth and differentiation status (with videos).2022Gastrointestinal endoscopy
  51. The Application of Two-Stage Operation for High-Risk Patients with Oesophageal Cancer Following Gastrectomy.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  52. Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening.2022Oncogene
  53. Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  54. Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer.2021Aging免费全文
  55. Long non-coding RNA LINC00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer.2021Bioengineered免费全文
  56. MicroRNA-1269b inhibits gastric cancer development through regulating methyltransferase-like 3 (METTL3).2021Bioengineered免费全文
  57. Silencing of long non-coding RNA HCP5 inhibits proliferation, invasion, migration, and promotes apoptosis via regulation of miR-299-3p/SMAD5 axis in gastric cancer cells.2021Bioengineered免费全文
  58. Identification of a novel immune prognostic model in gastric cancer.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  59. Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  60. Reconstruction of the esophagus of patients with middle thoracic esophageal carcinoma using the remnant stomach following Billroth II gastrectomy.2021Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  61. Accurate diagnosis and prognosis prediction of gastric cancer using deep learning on digital pathological images: A retrospective multicentre study.2021EBioMedicine免费全文
  62. Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer: a randomized controlled trial.2021EndoscopyRCT
  63. A deep learning-based system for identifying differentiation status and delineating the margins of early gastric cancer in magnifying narrow-band imaging endoscopy.2021Endoscopy
  64. MicroRNA-328-3p facilitates the progression of gastric cancer via KEAP1/NRF2 axis.2021Free radical research
  65. Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  66. Artificial intelligence in the diagnosis of gastric precancerous conditions by image-enhanced endoscopy: a multicenter, diagnostic study (with video).2021Gastrointestinal endoscopy
  67. Pyroptosis Patterns Characterized by Distinct Tumor Microenvironment Infiltration Landscapes in Gastric Cancer.2021Genes免费全文
  68. Having gastroesophageal cancer is associated with increased risk of severe COVID-19-related events in patients with digestive tract cancer: A multicenter, retrospective, cohort study.2021International journal of cancer
  69. Artificial intelligence in upper GI endoscopy - current status, challenges and future promise.2021Journal of gastroenterology and hepatology
  70. Proximal gastrectomy with double-tract reconstruction versus total gastrectomy for proximal early gastric cancer: A systematic review and meta-analysis.2021Medicine免费全文
  71. Identification of hub genes and construction of an mRNA-miRNA-lncRNA network of gastric carcinoma using integrated bioinformatics analysis.2021PloS one免费全文
  72. Identification of stem cell-related subtypes and risk scoring for gastric cancer based on stem genomic profiling.2021Stem cell research & therapy免费全文
  73. The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma.2021Technology in cancer research & treatment免费全文
  74. Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial.2021The lancet. Gastroenterology & hepatologyRCT
中文论文(未计入)3
  1. [Mucoepidermoid carcinoma of the stomach: report of two cases].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Hepatoid adenocarcinoma of the stomach metastatic to liver: a clinicopathological analysis of 3 cases].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Primary solid acinar rhabdomyosarcoma of stomach: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease正在招募NCT03972956牵头方2020-12 启动
  2. First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC已完成NCT06238752牵头方II期2021-03 启动
  3. Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)正在招募NCT07401199研究中心2026-02 启动
  4. Development of a Multimodal AI System for GIST Management已完成NCT07454967研究中心2026-03 启动
  5. Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis已完成NCT06109805研究中心2023-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.7%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 1120232024: 0020242025: 112025

武汉有 16 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

这些论文过半是实验室或动物研究。

牵头的论文5
  1. Comprehensive analysis of single-cell and bulk RNA sequencing uncover tumor microenvironment diversity in invasive Retinoblastoma.2025Scientific reports
  2. Highly Efficient Photodynamic Therapy with Mitochondria-Targeting Aggregation-Induced Emission Photosensitizer for Retinoblastoma.2023Advanced healthcare materials
  3. GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells.2022Oxidative medicine and cellular longevity
  4. The anticancer effects of 7-Methoxyheptaphylline against the human retinoblastoma cells are facilitated via S-phase cell cycle arrest, mitochondrial apoptosis and inhibition of Wnt/β-catenin signalling pathway.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  5. The Results of Pars Plana Vitrectomy in the Treatment of Intraocular Retinoblastoma: A Retrospective Study and Literature Review.2021Technology in cancer research & treatment
早期论文(2016–2020 年)4
  1. Inhibition of anticancer growth in Retinoblastoma cells by naturally occurring sesquiterpene nootkatone is mediated via autophagy, endogenous ROS production, cell cycle arrest and inhibition of NF-κB signalling pathway.2020Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  2. The anticancer effects of 7-Methoxyheptaphylline against the human retinoblastoma cells are facilitated via S-phase cell cycle arrest, mitochondrial apoptosis and inhibition of Wnt/β-catenin signalling pathway.2020Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  3. Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma.2020Medicine
  4. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.2019Biochemical and biophysical research communications
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma状态不明NCT04990271研究中心II期2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 31 篇,占 1.4%。

牵头论文
31
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 111120232024: 3320242025: 11112025

武汉有 22 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文31
  1. TRIM17 promotes the progression of osteosarcoma by regulating PDK1 m6A modification-mediated AKT/mTOR pathway activation through ubiquitination of FTO.2025Cell death & disease
  2. ABLIM1 promotes the proliferation, migration and invasion of osteosarcoma through DCC mediated activation of PI3K/AKT signaling pathway.2025Cellular signalling
  3. IRF2BPL inhibits proliferation, migration and invasion of osteosarcoma cells by inhibiting FOSL2-mediated PI3K/AKT pathway activation.2025Cellular signalling
  4. Bayesian Optimization-Enhanced Machine Learning for Osteosarcoma Risk Stratification Based on Sphingolipid Metabolism.2025Human mutation
  5. RNF207 promotes the proliferation, migration and invasion of osteosarcoma through KCNQ1 mediated activation of ERK/MEK signaling pathway.2025International immunopharmacology
  6. DUSP3 restrains the progression and stemness property of osteosarcoma through regulating EGFR/STAT3/SOX2 axis.2025International journal of biological sciences
  7. Bayesian-optimized deep learning for identifying essential genes of mitophagy and fostering therapies to combat drug resistance in human cancers.2025Journal of cellular and molecular medicine
  8. HMGCL activates autophagy in osteosarcoma through β-HB mediated inhibition of the PI3K/AKT/mTOR signaling pathway.2025Journal of translational medicine
  9. Research progress on cancer-associated fibroblasts in osteosarcoma.2025Oncology research
  10. Constructing a prognostic model for osteosarcoma based on centrosome-related genes and identifying potential therapeutic targets of paclitaxel.2025Scientific reports
  11. The homeobox family gene signature predicts the prognosis of osteosarcoma and correlates with immune invasion.2025Scientific reports
  12. ZNF692 promotes osteosarcoma cell proliferation, migration, and invasion through TNK2-mediated activation of the MEK/ERK pathway.2024Biology direct
  13. SLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.2024Journal of translational medicine
  14. CGREF1 modulates osteosarcoma proliferation by regulating the cell cycle through the Wnt/β-catenin signaling pathway.2024Molecular medicine (Cambridge, Mass.)
  15. Incidental detection of Ewing sarcoma in the thoracic spinal cord by 18F-FDG PET/CT in a pediatric patient with cerebral infarction.2023Asian journal of surgery
  16. Construction of a prognostic risk score model based on the ARHGAP family to predict the survival of osteosarcoma.2023BMC cancer
  17. TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling.2023Cell death & disease
  18. CircTNPO1 promotes the tumorigenesis of osteosarcoma by sequestering miR-578 to upregulate WNT5A expression.2023Cellular signalling
  19. Gambogenic acid induces cell death in human osteosarcoma through altering iron metabolism, disturbing the redox balance, and activating the P53 signaling pathway.2023Chemico-biological interactions
  20. CircUSP48 promotes malignant behavior by regulating CYR61 via miR-365 in osteosarcoma.2023Functional & integrative genomics
  21. METTL3-mediated m6A modification of circRNF220 modulates miR-330-5p/survivin axis to promote osteosarcoma progression.2023Journal of cancer research and clinical oncology
  22. Silencing circUSP48 suppresses osteosarcoma progression by regulating the miR-335/ smad nuclear interacting protein 1 pathway.2023Journal of clinical laboratory analysis
  23. Circadian rhythm-associated lncRNA RP11-414H17.5 as a key therapeutic target in osteosarcoma affects the tumor immune microenvironment and enhances malignancy.2023Journal of orthopaedic surgery and research
  24. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway.2023Molecular medicine (Cambridge, Mass.)
  25. Identification and validation of long noncoding RNA AC083900.1 and RP11-283C24.1 for prediction of progression of osteosarcoma.2023Mutation research
  26. Silencing long non-coding RNA LINC00960 inhibits osteosarcoma proliferation by sponging miR-107 to downregulate SALL4.2022Biochemical and biophysical research communications
  27. Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature.2022Frontiers in endocrinology
  28. Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma.2022Human & experimental toxicology
  29. Long non-coding RNA NR2F2-AS1 regulates human osteosarcoma growth and metastasis through miR-425-5p-mediated HMGB2.2022International journal of clinical oncology
  30. Human umbilical vein endothelial cells derived-exosomes promote osteosarcoma cell stemness by activating Notch signaling pathway.2021Bioengineered
  31. MicroRNA-629-5p promotes osteosarcoma proliferation and migration by targeting caveolin 1.2021Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
早期论文(2016–2020 年)20
  1. Proscillaridin A induces apoptosis and inhibits the metastasis of osteosarcoma in vitro and in vivo.2020Biochemical and biophysical research communications
  2. CDKN2B-AS1 Exerts Oncogenic Role in Osteosarcoma by Promoting Cell Proliferation and Epithelial to Mesenchymal Transition.2020Cancer biotherapy & radiopharmaceuticals
  3. Circ_0010220-mediated miR-503-5p/CDCA4 axis contributes to osteosarcoma progression tumorigenesis.2020Gene
  4. Hsa-let-7g promotes osteosarcoma by reducing HOXB1 to activate NF-kB pathway.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. Relationship between red cell distribution width and prognosis of patients with osteosarcoma.2019Bioscience reports
  6. The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephrin Reverse Signaling.2019Molecular cancer research : MCR
  7. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.2019Molecular carcinogenesis
  8. Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice.2018Biochemical and biophysical research communications
  9. LncRNA SNHG12 promotes tumorigenesis and metastasis in osteosarcoma by upregulating Notch2 by sponging miR-195-5p.2018Biochemical and biophysical research communications
  10. Cinobufagin Induces Apoptosis in Osteosarcoma Cells Via the Mitochondria-Mediated Apoptotic Pathway.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  11. Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone.2018Medical science monitor : international medical journal of experimental and clinical research
  12. miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2.2018Scientific reports
  13. Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling.2017European journal of pharmacology
  14. SOX5 promotes epithelial-mesenchymal transition in osteosarcoma via regulation of Snail.2017Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  15. LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27.2017Journal of orthopaedic surgery and research
  16. High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma.2017Molecular medicine reports
  17. MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma.2017Molecular medicine reports
  18. Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells.2017Scientific reports
  19. Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NF-κB signaling pathway.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  20. Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.2016Oncotarget

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

武汉有 9 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.9%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 5520232024: 1120242025: 002025

武汉有 10 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文10
  1. PERK inhibition mitigates acrylamide-induced tau phosphorylation and synaptic deficits via the GSK-3β and ATF4 pathways in human neuroblastoma SH-SY5Y cells.2026Ecotoxicology and environmental safety
  2. L116 Deletion in CSPα Promotes α-Synuclein Aggregation and Neurodegeneration.2024Molecular neurobiology
  3. Inhibition of PINK1-Mediated Mitophagy Contributes to Postoperative Cognitive Dysfunction through Activation of Caspase-3/GSDME-Dependent Pyroptosis.2023ACS chemical neuroscience
  4. Neuronal-specific TNFAIP1 ablation attenuates postoperative cognitive dysfunction via targeting SNAP25 for K48-linked ubiquitination.2023Cell communication and signaling : CCS
  5. Exposure to dithiocarbamate fungicide maneb in vitro and in vivo: Neuronal apoptosis and underlying mechanisms.2023Environment international
  6. SNAP25 ameliorates postoperative cognitive dysfunction by facilitating PINK1-dependent mitophagy and impeding caspase-3/GSDME-dependent pyroptosis.2023Experimental neurology
  7. Retinoic Acid Prevents α-Synuclein Preformed Fibrils-Induced Toxicity via Inhibiting STAT1-PARP1 Signaling.2023Molecular neurobiology
  8. Exposure to the environmentally toxic pesticide maneb induces Parkinson's disease-like neurotoxicity in mice: A combined proteomic and metabolomic analysis.2022Chemosphere
  9. Curcumin Attenuates the PERK-eIF2α Signaling to Relieve Acrylamide-Induced Neurotoxicity in SH‑SY5Y Neuroblastoma Cells.2022Neurochemical research
  10. Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma.2021Journal of cellular physiology

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

武汉有 6 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年没有牵头重症肌无力的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

武汉有 3 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06447597

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、遵义、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.正在招募NCT06447597研究中心II/III期2024-07 启动
  2. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis进行中,不再招募NCT06558279研究中心III期2024-09 启动
  3. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动
  4. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis进行中,不再招募NCT05070858研究中心III期2021-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

武汉有 5 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

武汉有 9 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

武汉有 6 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

武汉有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年没有牵头Alport 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 3 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Analysis of ultrastructural features of glomeruli in different genotypic Alport syndrome].2019Zhonghua bing li xue za zhi = Chinese journal of pathology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

武汉有 8 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 6 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

武汉有 4 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

武汉有 3 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

武汉大学人民医院

Renmin Hospital of Wuhan University

武汉

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
RenMin Hospital of WuHan University; Renmin Hospital of WuhanUniversity; PET-CT/MRI Center Renmin Hospital of Wuhan University Wuhan; Qianjiang Hospital Affiliated to Renmin Hospital of Wuhan University; East Hospital of Renmin Hospital of Wuhan University; First Affiliated Hospital of Wuhan University; Hubei General Hospital; Hubei Provincial People's Hospital

提出更正下载数据